{"id":253044,"date":"2025-01-10T01:00:07","date_gmt":"2025-01-10T00:00:07","guid":{"rendered":"https:\/\/r3i.org\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/"},"modified":"2025-02-05T23:04:16","modified_gmt":"2025-02-05T22:04:16","slug":"charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2","status":"publish","type":"page","link":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/","title":{"rendered":"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbHeader\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bb35f37621-1062-4ae6-955d-76a3167a2aa8&#8243; background_image=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/video-2562034_1280.jpg\u00bb parallax=\u00bbon\u00bb min_height=\u00bb158px\u00bb height=\u00bb225px\u00bb custom_padding=\u00bb6vw||6vw||true|false\u00bb collapsed=\u00bbon\u00bb global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22background_color_gradient_stops%22%93}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-69px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3&#8243; _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbCharlas\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbbe7faa8d-05f5-42a0-9582-c8e8739f13b6&#8243; title_font=\u00bbPoppins||||||||\u00bb title_text_align=\u00bbleft\u00bb title_text_color=\u00bb#FFFFFF\u00bb title_font_size=\u00bb47px\u00bb custom_padding=\u00bb12px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_heading][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.27.3&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb-49px|||||\u00bb custom_padding=\u00bb2px||54px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_3_text_color=\u00bbgcid-primary-color\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22header_3_text_color%22%93}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<h3 style=\"text-align: center;\">Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb][et_pb_column _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb type=\u00bb4_4&#8243;][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3i-27-Session-6-Tokgozoglu.mp4&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0&#8243; sticky_enabled=\u00bb0&#8243; title_text=\u00bbR3i 27 Session 6 Tokgozoglu\u00bb][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000&#8243; header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb-22px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<h5 style=\"text-align: center;\">Reducci\u00f3n del riesgo cardiovascular en la diabetes tipo 2 mediante la disminuci\u00f3n de la glucosa: \u00bfimporta el f\u00e1rmaco?<\/h5>\n<h6 style=\"text-align: center;\"><spanaptos narrow=\"\" arial=\"\" font-weight:normal=\"\" font-style:normal=\"\" data-sheets-root=\"1\">2023 &#8211; Lale Tokgozoglu<\/spanaptos><\/h6>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\u00bb1_2,1_2&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_2&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3i-29-Session-6-Eckel.mp4&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb hover_enabled=\u00bb0&#8243; border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb title_text=\u00bbR3i 29 Session 6 Eckel\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000&#8243; header_5_font_size=\u00bb18px\u00bb header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<h5 style=\"text-align: center;\">Comprender los efectos protectores en la enfermedad renal diab\u00e9tica: de los biomarcadores a los resultados cl\u00ednicos<\/h5>\n<h6 style=\"text-align: center;\"><spanaptos narrow=\"\" arial=\"\" font-weight:normal=\"\" font-style:normal=\"\" data-sheets-root=\"1\">2023 &#8211; Robert Eckel<\/spanaptos><\/h6>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_2&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_video src=\u00bbhttps:\/\/r3i.org\/wp-content\/uploads\/2025\/01\/R3i-30-Session-6-Sharma.mp4&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb||0px|||\u00bb hover_enabled=\u00bb0&#8243; border_radii=\u00bbon|11px|11px|11px|11px\u00bb global_colors_info=\u00bb{}\u00bb title_text=\u00bbR3i 30 Session 6 Sharma\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_video][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_5_text_color=\u00bb#000000&#8243; header_6_text_color=\u00bbgcid-secondary-color\u00bb custom_margin=\u00bb3px||-1px||false|false\u00bb custom_padding=\u00bb0px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{%22gcid-primary-color%22:%91%22quote_text_color%22,%22quote_text_color%22%93,%22gcid-secondary-color%22:%91%22header_6_text_color%22%93}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<h5 style=\"text-align: center;\">Nuevas terapias reductoras de la glucosa en la diabetes de tipo 2: conclusiones de los ensayos cl\u00ednicos<\/h5>\n<h6 style=\"text-align: center;\"><spanaptos narrow=\"\" arial=\"\" font-weight:normal=\"\" font-style:normal=\"\" data-sheets-root=\"1\">2023 &#8211; Abhinav Sharma<\/spanaptos><\/h6>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2Reducci\u00f3n del riesgo cardiovascular en la diabetes tipo 2 mediante la disminuci\u00f3n de la glucosa: \u00bfimporta el f\u00e1rmaco? 2023 &#8211; Lale TokgozogluComprender los efectos protectores en la enfermedad renal diab\u00e9tica: de los biomarcadores a los resultados cl\u00ednicos 2023 &#8211; Robert EckelNuevas terapias reductoras de la [&hellip;]<\/p>\n","protected":false},"author":258497324,"featured_media":0,"parent":253017,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","_crdt_document":"","jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-253044","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I\" \/>\n<meta property=\"og:description\" content=\"Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2Reducci\u00f3n del riesgo cardiovascular en la diabetes tipo 2 mediante la disminuci\u00f3n de la glucosa: \u00bfimporta el f\u00e1rmaco? 2023 - Lale TokgozogluComprender los efectos protectores en la enfermedad renal diab\u00e9tica: de los biomarcadores a los resultados cl\u00ednicos 2023 - Robert EckelNuevas terapias reductoras de la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/\" \/>\n<meta property=\"og:site_name\" content=\"R3I\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-05T22:04:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/pagina-de-inicio-de-las-charlas\\\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\\\/\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/pagina-de-inicio-de-las-charlas\\\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\\\/\",\"name\":\"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\"},\"datePublished\":\"2025-01-10T00:00:07+00:00\",\"dateModified\":\"2025-02-05T22:04:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/pagina-de-inicio-de-las-charlas\\\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/r3i.org\\\/es\\\/pagina-de-inicio-de-las-charlas\\\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/pagina-de-inicio-de-las-charlas\\\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/r3i.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"P\u00e1gina de inicio de las Charlas\",\"item\":\"https:\\\/\\\/r3i.org\\\/es\\\/talks-homepage\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"name\":\"R3I\",\"description\":\"Residual Risk Reduction Initiative\",\"publisher\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/r3i.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#organization\",\"name\":\"R3I\",\"url\":\"https:\\\/\\\/r3i.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/r3i.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1\",\"width\":1601,\"height\":834,\"caption\":\"R3I\"},\"image\":{\"@id\":\"https:\\\/\\\/r3i.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/","og_locale":"es_ES","og_type":"article","og_title":"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I","og_description":"Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2Reducci\u00f3n del riesgo cardiovascular en la diabetes tipo 2 mediante la disminuci\u00f3n de la glucosa: \u00bfimporta el f\u00e1rmaco? 2023 - Lale TokgozogluComprender los efectos protectores en la enfermedad renal diab\u00e9tica: de los biomarcadores a los resultados cl\u00ednicos 2023 - Robert EckelNuevas terapias reductoras de la [&hellip;]","og_url":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/","og_site_name":"R3I","article_modified_time":"2025-02-05T22:04:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/","url":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/","name":"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2 - R3I","isPartOf":{"@id":"https:\/\/r3i.org\/es\/#website"},"datePublished":"2025-01-10T00:00:07+00:00","dateModified":"2025-02-05T22:04:16+00:00","breadcrumb":{"@id":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/r3i.org\/es\/pagina-de-inicio-de-las-charlas\/charlas-reduccion-del-riesgo-cardiorrenal-con-hipoglucemiantes-en-la-diabetes-tipo-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/r3i.org\/es\/"},{"@type":"ListItem","position":2,"name":"P\u00e1gina de inicio de las Charlas","item":"https:\/\/r3i.org\/es\/talks-homepage\/"},{"@type":"ListItem","position":3,"name":"Charlas : Reducci\u00f3n del riesgo cardiorrenal con hipoglucemiantes en la diabetes tipo 2"}]},{"@type":"WebSite","@id":"https:\/\/r3i.org\/es\/#website","url":"https:\/\/r3i.org\/es\/","name":"R3I","description":"Residual Risk Reduction Initiative","publisher":{"@id":"https:\/\/r3i.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/r3i.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/r3i.org\/es\/#organization","name":"R3I","url":"https:\/\/r3i.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","contentUrl":"https:\/\/i0.wp.com\/r3i.org\/wp-content\/uploads\/2024\/11\/r3i-logo-transp-1.png?fit=1601%2C834&ssl=1","width":1601,"height":834,"caption":"R3I"},"image":{"@id":"https:\/\/r3i.org\/es\/#\/schema\/logo\/image\/"}}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/Pgbfv2-13Pm","jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/users\/258497324"}],"replies":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/comments?post=253044"}],"version-history":[{"count":2,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253044\/revisions"}],"predecessor-version":[{"id":253046,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253044\/revisions\/253046"}],"up":[{"embeddable":true,"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/pages\/253017"}],"wp:attachment":[{"href":"https:\/\/r3i.org\/es\/wp-json\/wp\/v2\/media?parent=253044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}